Head & Neck Cancers | Clinical

KEYNOTE B10 Evaluates New Triplet Regimen for Patients With HNSCC

November 01, 2022

In an interview with Targeted Oncology, Marcin Dzienis, MD, further discussed the phase 4 trial of pembrolizumab plus carboplatin and paclitaxel in patients with recurrent/metastatic head and neck squamous cell carcinoma.